Form 4: Orchestra BioMed CEO David Hochman Acquires 5,000 Shares

Orchestra BioMed's CEO, David Hochman, purchased 5,000 shares of common stock at an average price of $4.91 on December 18, 2024.

Summary

• David Hochman, CEO of Orchestra BioMed Holdings, Inc., acquired 5,000 shares of common stock on December 18, 2024.
• The shares were purchased at a weighted average price of $4.91, with individual transaction prices ranging from $4.88 to $4.94.
• Following the transaction, Mr. Hochman directly owns 575,498 shares of common stock.
• He also indirectly owns 335,002 shares through the DPH 2008 Trust and 9,140 shares through other family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase could be seen as a positive sign, but it's a routine transaction and doesn't indicate a major shift in the company's outlook.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the biomedical industry.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• Similar filings are made by executives at companies like Medtronic, Boston Scientific, and Abbott, when they buy or sell shares of their respective companies.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Orchestra BioMed, David Hochman, share purchase, insider trading, common stock, SEC Form 4, executive, biomedical